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Targeting the metabolic pathways in cancer is actually the most contemporary topic of drug discovery. The unique metabolic requirement of cancer cells
to sustain proliferation and survival pave the way for innovative therapeutic intervention. In this regard, we have contributed to the emergence of new
facet of cancer adaptation and evasion to anti-angiogenic therapy. We previously show that tumor adaptation to angiogenesis inhibitors relies on a
metabolic reprogramming towards de novo lipogenesis after treatment cessation that was associated with tumor aggressiveness. The concept of targeting
lipid metabolism to improve efficacy of targeted therapy has been validated by sequential targeting VEGF pathway and FASN in cancers. Whereas FASN is
recognized as an important target in the development of anticancer drug for many types of human cancers, its complete inhibition has showed poor
pharmacokinetics with heavy side effects, highlighting the need for the identification of new therapeutic targets that inhibit lipid metabolism.
SCD1 expression seems to be important for cancer cells to sustain the oxidative stress occurring after RTKIs treatment withdrawal and re-oxygenation.
SCD1 inhibition reduces the level of neo synthesized of saturated lipids and MUFA/PUFA. Thus, interaction of MUFA/PUFA with ROS enhances lipid
peroxidation end products (MDA), which correlates with increased tumor aggressiveness after tumor re-oxygenation. Interestingly, inhibition of SCD1 by
shRNA or by pharmacological inhibitors or administration of antioxidant resulted in increased efficacy of RTKI post treatment.
Results
A lipidomic approaches (LC-
MS (A) and MSI (B)) were
applied on tumor extracts or
sections after treatment
cessation. Data show an
increase in mono- and poly-
unsaturated fatty acids (A) in
RTKIs treated tumors. RTKIs
treatments induces a
complete change in lipids
species (B) within tumors.
Lipidomics analyses SCD1 expression1 2
3
SCD1, a key Stearoyl-CoA Desaturase enzyme that inserts double bonds into acyl-CoA chains (A) is upregulated after
tumor re-oxygenation. Data from microarray analysis (B), western blot (C) and qRT-PCR (D) were performed on tumor
extracts. SCD1 expression was also validated in human breast cancer samples with a marked increase in both primary




Inhibition of SCD1 reduces tumor growth
Inhibition of SCD1 by shRNA or by small SCD1 inhibitors in LLC and MDA-MB231 cancer cells showed a marked
reduction in spheroid migration in vitro (A). In vivo, primary tumor growth and re-growth after re-oxygenation
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LLC sh SCD1 
cells
LLC tumor sh CTRL/sh SCD1 growth in vivo MDA-MB231 tumor sh CTRL/sh SCD1 growth in vivo 























MDA-MB231 sh CTRL W sunitinib
Vehicle RTKI
SCD1 mRNA
SCD1 IH  staining on human tissues :
Unsaturated lipids are known to play a role in cell membrane fluidity and can be peroxided by reactive
oxygen species (ROS). Interestingly, the levels of oxidative stress markers SOD1, catalase, TxNiP, GADD45
were increased in tumors during and after anti-angiogenic treatment (A). Measurement of the lipid
peroxidation product malondialdehyde (MDA) showed a marked increase in tumors after re-oxygenation
(B). Importantly, administration of anti-oxidant NAC mimics the effect of SCD1 inhibition in vivo by
enhancing the efficacy of anti-angiogenic treatments (C).



















Malondialdehyde dosage in LLC tumors extracts

















LLC tumor  growth in vivo with SCD1 inhibitor 
MDA-MB231 tumor  growth in vivo with SCD1 inhibitor 
Vehicle InhSCD1 Sunitinib Sunitinib+InhSCD1
































MDA-MB231 tumor growth in vivo (RTKI combines with antioxydant)
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Vehicle
Sunitinib
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Sunitinib + Nac
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